XARELTO TABLET

Nchi: Kanada

Lugha: Kiingereza

Chanzo: Health Canada

Viambatanisho vya kazi:

RIVAROXABAN

Inapatikana kutoka:

BAYER INC

ATC kanuni:

B01AF01

INN (Jina la Kimataifa):

RIVAROXABAN

Kipimo:

10MG

Dawa fomu:

TABLET

Tungo:

RIVAROXABAN 10MG

Njia ya uendeshaji:

ORAL

Vitengo katika mfuko:

50

Dawa ya aina:

Prescription

Eneo la matibabu:

Direct Factor Xa Inhibitors

Bidhaa muhtasari:

Active ingredient group (AIG) number: 0152487001; AHFS:

Idhini hali ya:

APPROVED

Idhini ya tarehe:

2008-09-15

Tabia za bidhaa

_XARELTO (rivaroxaban tablets; rivaroxaban granules for oral
suspension) _
_Page 1 of 119_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
XARELTO®
Rivaroxaban tablets
Tablets 2.5 mg, 10 mg, 15 mg and 20 mg, Oral
Rivaroxaban granules for oral suspension
Granules for oral suspension, 1mg/mL when reconstituted, Oral
Anticoagulant
(ATC Classification: B01AF01)
Bayer Inc.
2920 Matheson Boulevard East
Mississauga, Ontario
L4W 5R6
http://www.bayer.ca
Date of Initial Authorization:
SEP 15, 2008
Date of Revision:
April 17, 2023
Submission Control Number: 268349
© 2023, Bayer Inc.
®
TM see www.bayer.ca/tm-mc
_XARELTO (rivaroxaban tablets; rivaroxaban granules for oral
suspension) _
_Page 2 of 119_
RECENT MAJOR LABEL CHANGES
4 DOSAGE AND ADMINISTRATION, 4.3 Reconstitution
04/2023
7 WARNINGS AND PRECAUTIONS, Bleeding
12/2021
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.....................................................................................................
2
TABLE OF CONTENTS
.......................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
..............................................................................
4
1 INDICATIONS
................................................................................................................................
4
1.1 Pediatrics
.....................................................................................................................................
4
1.2 Geriatrics
.....................................................................................................................................
5
2 CONTRAINDICATIONS
..................................................................................................................
5
4 DOSAGE AND ADMINISTRATION
..........................................................................................